(Q37481248)

20 August 2017

title

Aglycosylated antibodies and the methods of making and using them: WO2008030564. (English)

1 reference

20 August 2017

1 reference

Roy Jefferis

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

Expert Opinion on Therapeutic Patents

20 August 2017

published in

1 reference

20 August 2017

volume

19

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

101-105

1 reference

Potent antibody therapeutics by design

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

"Antibodies--Europe. Engineering the next generation of antibodies".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

Development trends for monoclonal antibody cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

Glycosylation of recombinant antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

Antibody therapeutics: isotype and glycoform selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

Human antibody-Fc receptor interactions illuminated by crystal structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

Interactions of immunoglobulins outside the antigen-combining site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

Structural characterization of a mutated, ADCC-enhanced human Fc fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802592408

10.1517/13543770802592408

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference